Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
4
×
Tags
alnylam pharmaceuticals
boston
boston blog main
boston top stories
clinical trials
fda
life sciences
national blog main
patisiran
4
×
rna interference
4
×
hereditary transthyretin amyloidosis
national top stories
akcea therapeutics
biotech
drugs
inotersen
new york blog main
new york top stories
onpattro
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
tafamidis
vyndaqel
acute hepatic porphyrias
akin akinc
alexion pharmaceuticals
aminolevulinic acid
andrew fire
barry greene
boehringer ingelheim
boston university
craig mello
dan ollendorf
deals
dicerna pharamceuticals
givosiran
hepatitis b
hepatitis b virus
What
alnylam
drug
fda
medicine
pharmaceuticals
ago
rna
rnai
afternoon
alnylam’s
approval
approve
approved
awaits
biological
caught
causing
crossed
decades
decision
dicerna
discovered
disease
eye
fingers
friday
gene
gets
hepatitis
historic
history
indicated
intended
interference
landmark
making
medicines
nod
ok
onpattro
Language
unset
Current search:
patisiran
×
photo
×
" rna interference "
×
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision